Viridian Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
REVEAL-1 phase III trial in active thyroid eye disease met its primary endpoint, with both Q4 and Q8 weekly subcutaneous regimens of ele showing robust, rapid, and clinically meaningful proptosis and diplopia responses, and a favorable safety profile. Home administration in as few as three doses could expand the $2B TED market.
-
Lead IV therapy for TED targets June 30 PDUFA date with launch readiness nearly complete. Two phase III subQ readouts are expected in Q1 and Q2, aiming to expand market reach. Pipeline includes TSHR and FcRn programs, with key data and regulatory milestones anticipated this year.
-
Significant phase III milestones for TED therapies are expected in Q1 and Q2, with a commercial launch of the IV program targeted for mid-year. Reduced treatment burden and rapid efficacy differentiate the pipeline, while global expansion and new mechanisms like TSHR offer future growth opportunities.
Fiscal Year 2025
-
Strong clinical results and rapid treatment effects support regulatory progress, with subcutaneous and IV programs targeting a $2B U.S. market and global expansion. Financially, recent deals and an equity raise position the company for profitability and continued portfolio execution.
-
The conference highlighted strong progress in TED and FcRn portfolios, with Veligrotug IV on track for a potential mid-2026 launch pending priority review, and subQ pivotal readouts expected in early 2026. Robust clinical data, market expansion strategies, and upcoming FcRn milestones were emphasized.
-
The company is advancing a robust autoimmune pipeline, highlighted by a BLA submission for its TED therapy and a strong FCRN portfolio. With a $2B TED market, rapid adoption is expected due to product differentiation and focused commercial strategy. Financially, recent royalty and equity deals position the company for break-even and profitability.
-
Advancing a robust portfolio with positive phase three data, the company is preparing for a BLA filing and potential commercial launch next year. Differentiated by fewer infusions, lower drug dosage, and a strong safety profile, the product is positioned to capture a significant share in a $2 billion market, with global expansion and subcutaneous options in development.
-
Strong phase III data for TED program show rapid and durable efficacy with a favorable safety profile, supporting a 2025 commercial launch. SUBQ phase III studies are on track for 2026, offering self-administration and expanded access. FcRn programs advance with key data expected in 2024.
-
Multiple positive phase 3 results in TED with rapid onset and strong safety support a second-half 2024 BLA filing. SubQ and FcRn programs advance, with subQ aiming for major market share via autoinjector and first human FcRn data due Q3 2024.
-
Two positive phase 3 studies in thyroid eye disease showed robust efficacy and safety, supporting a BLA submission in H2. SubQ and FcRn programs advance, with global expansion and a focused commercial strategy planned. Competitive landscape and payer positioning are favorable.
Fiscal Year 2024
-
Positive Phase 3 program design for VRDN-003 was announced, with simultaneous trials in active and chronic TED starting in August and top-line data expected in early 2026. The subcutaneous, auto-injector format is expected to drive market expansion, while the company advances its FcRn portfolio and prepares for commercial launch.
-
Phase III data for the IV program is expected in September, with strong efficacy and safety seen in phase II. The Sub-Q program is advancing to phase III, offering flexible dosing and patient convenience, while market dynamics favor rapid adoption of new formulations.